Harnessing liver-on-a-chip models for drug safety

This webinar is now available on demand.

Improving data translatability between preclinical testing and clinical applications is crucial for advancing drug safety assessment. A major challenge lies in enhancing the predictivity of standard toxicology workflows to better identify complex or species-specific toxicity risks. In this webinar, Emily Richardson will describe how liver microphysiological systems (MPS), also called liver-on-a-chip technology, can improve safety testing by providing greater physiological relevance, longevity, and cross-species insights to support research decisions and therapeutic development.

Topics to be covered:

• Addressing workflow limitations with the routine use of human liver MPS in toxicology testing
• Overcoming drug development challenges with insights provided by liver MPS
• Leveraging species-specific MPS and mechanistic endpoints to improve data translatability and prevent misclassification of drugs 

Speakers:

Rhiannon Hardwick, PhD, DABT
Scientific Associate Director, Discovery Toxicology
Bristol Myers Squibb

Emily Richardson, PhD
Lead Scientist
CN Bio

Tomasz Kostrzewski, PhD
Chief Scientific Officer
CN Bio